Utilizing T(H)9 cells as a novel therapeutic strategy for malignancies

T(H)9 cells join the ever-growing list of CD4(+) T helper subsets and primarily mediate anti-parasite immune responses. We have recently demonstrated that tumor-specific T(H)9 cells induce a CCL20-CCR6-dependent regulation of DCs while stimulating CD8(+) T cell-mediated antitumor immunity. These fin...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Yong, Yi, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661147/
https://www.ncbi.nlm.nih.gov/pubmed/23802062
http://dx.doi.org/10.4161/onci.23084
_version_ 1782270635293016064
author Lu, Yong
Yi, Qing
author_facet Lu, Yong
Yi, Qing
author_sort Lu, Yong
collection PubMed
description T(H)9 cells join the ever-growing list of CD4(+) T helper subsets and primarily mediate anti-parasite immune responses. We have recently demonstrated that tumor-specific T(H)9 cells induce a CCL20-CCR6-dependent regulation of DCs while stimulating CD8(+) T cell-mediated antitumor immunity. These findings offer a novel immunotherapeutic strategy against cancer.
format Online
Article
Text
id pubmed-3661147
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-36611472013-06-25 Utilizing T(H)9 cells as a novel therapeutic strategy for malignancies Lu, Yong Yi, Qing Oncoimmunology Author's View T(H)9 cells join the ever-growing list of CD4(+) T helper subsets and primarily mediate anti-parasite immune responses. We have recently demonstrated that tumor-specific T(H)9 cells induce a CCL20-CCR6-dependent regulation of DCs while stimulating CD8(+) T cell-mediated antitumor immunity. These findings offer a novel immunotherapeutic strategy against cancer. Landes Bioscience 2013-03-01 2013-03-01 /pmc/articles/PMC3661147/ /pubmed/23802062 http://dx.doi.org/10.4161/onci.23084 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Lu, Yong
Yi, Qing
Utilizing T(H)9 cells as a novel therapeutic strategy for malignancies
title Utilizing T(H)9 cells as a novel therapeutic strategy for malignancies
title_full Utilizing T(H)9 cells as a novel therapeutic strategy for malignancies
title_fullStr Utilizing T(H)9 cells as a novel therapeutic strategy for malignancies
title_full_unstemmed Utilizing T(H)9 cells as a novel therapeutic strategy for malignancies
title_short Utilizing T(H)9 cells as a novel therapeutic strategy for malignancies
title_sort utilizing t(h)9 cells as a novel therapeutic strategy for malignancies
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661147/
https://www.ncbi.nlm.nih.gov/pubmed/23802062
http://dx.doi.org/10.4161/onci.23084
work_keys_str_mv AT luyong utilizingth9cellsasanoveltherapeuticstrategyformalignancies
AT yiqing utilizingth9cellsasanoveltherapeuticstrategyformalignancies

Ejemplares similares